E-merge Capital Partners

What E-merge Capital Partners does

E-merge Capital Partners is a privately held venture capital and growth equity firm founded in 2021 that invests in early-stage medical device companies and technologies. The firm operates from a Solana Beach, California headquarters (535 Stevens Ave. W.) and a secondary office in Tacoma, Washington (820 A St., Ste. 720), with a reported headcount of 1-10. Its investing vehicle is E-merge Fund I, whose first closing was announced on May 19, 2021; the fund size is not publicly disclosed. The partnership is led by Managing Partners Brad Klos and John M. Xitco, supported by Venture Partners Randy Werneth and Rob Abrams, a Limited Partner/Advisor (Jim Pray, formerly President of Penumbra), and formal Business and Medical Advisory Boards spanning IP, regulatory/QA, venture lending, operations, commercialization, vascular surgery, interventional cardiology, and interventional radiology.

E-merge's commercial model is to make direct equity investments in pre-commercial and early-commercial medical device companies and to deliver active operational support through an integrated ecosystem of partners: Evolve Medtech (engineering, product development, regulatory and quality), Pathway Medtech (ISO 13485:2016 contract manufacturing), Coastline International (high-volume manufacturing in Tijuana, Mexico), and MMC International Services (early-stage clinical trial design and execution across the US, Europe, South America, Australia, New Zealand, and Asia). The active portfolio comprises six companies spanning orthopedic surgery (Retract Ortho), cardiac resynchronization therapy (Maxwell Biomedical), venous stenting catheters (Vector Vascular), percutaneous arteriovenous fistula creation (Venova Medical), neuro and peripheral vascular access (Clearpath Vascular), and venous debulking (Alaris Vascular). Three portfolio companies have been acquired by strategic medical device buyers: Traverse Vascular (June 2022), SinglePass Transseptal (December 2023), and Boa Medical (April 2025, structured as a build-to-buy).

E-merge's revenue model is transaction-based venture capital economics, generating returns through equity ownership in portfolio companies that exit via acquisition or other liquidity events; management fees and carried interest on E-merge Fund I are the underlying revenue mechanics. The firm does not have publicly disclosed pricing, products, or services. Distribution is through direct investment via the firm's venture fund, with marketing confined to LinkedIn. No AI/ML capabilities, apps, APIs, public certifications (the ISO 13485 certification belongs to partner Pathway Medtech), regulatory actions, or institutional parent company are disclosed in the source material.

Name

E-merge Capital Partners

Legal name

E-merge Capital Management, LLC

Website

https://e-mergecapital.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

E-merge Capital Partners is a privately held venture capital and growth equity firm that invests in early-stage medical device companies via E-merge Fund I. Founded in 2021 and based in Solana Beach, California, the firm combines capital with an integrated operating stack of engineering, manufacturing, and clinical partners.

Ownership category

akta.pro rank

Product category

Venture Capital / Medical Device Investment

NAICS

All Other Financial Investment Activities (52399)

SIC

Investment Advice (6282)

akta.pro industry

PRIMARYFSANAAAD

Sector-Focused Venture Capital (Vertical Specialists)

Financial & Insurance/Private Equity & Venture Capital/Venture Capital Firms

SECONDARYFSANAHAG

Corporate M&A / Venture Build-to-Buy Programs (Acqui-hire, option-to-acquire)

Financial & Insurance/Private Equity & Venture Capital/Corporate Venture Capital (CVC)

Keywords

• Venture capital investing
• Medical device funding
• Growth equity firm
• Early-stage investments
• Portfolio management

Headquarters

HQ city

Solana Beach

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Venture Capital Fund Returns: E-merge Capital generates returns through equity investments in early-stage medical device companies. The firm takes ownership stakes in portfolio companies and realizes returns upon exits through acquisitions or other liquidity events. Notable exits include SinglePass Transseptal (December 2023) and Boa Medical (April 2025).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

E-merge Capital Partners is a venture capital and growth equity firm that invests in early-stage medical device companies and technologies. The firm operates E-merge Fund I, providing equity capital along with operational support through a network of business and physician advisors to help portfolio companies navigate clinical development, regulatory pathways, and strategic partnerships, with returns realized through acquisition exits.

Product overview

E-merge Capital Partners is a venture capital and growth equity firm that invests in innovative medical device companies and technologies. The firm operates E-merge Fund I, a venture fund dedicated to early-stage medical device products and companies. Its portfolio includes both active investments (Retract Ortho, Maxwell Biomedical, Vector Vascular, Venova Medical, Clearpath Vascular, Alaris Vascular) and successfully exited companies (SinglePass Transseptal acquired December 2023, Boa Medical acquired April 2025, Traverse Vascular acquired June 2022). The firm provides access to business and physician advisors and leverages a network of trusted relationships with vendors, consultants, investors, and strategic medical device companies.

Differentiator

Problem solved

Functional benefit

Products and services

• E-merge Fund I

Quantifiable outcome

• Three successful acquisitions (Traverse Vascular June 2022, SinglePass Transseptal Dec 2023, Boa Medical April 2025)
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Four partnerships are on record, tiered core and supporting.

• Evolve MedtechcoreStrategic or Co-development Partner · 19 May 2021Evolve Medtech supports e-merge portfolio companies with engineering, product development, regulatory and quality expertise, leveraging the team's expertise in design-for-manufacturing principles. Evolve's facility is based in Solana Beach, North County San Diego, center of the region's life science ecosystem. Managing Partner Brad Klos also serves as Managing Partner at Evolve Medtech Partners.
• Pathway MedtechcoreStrategic or Co-development PartnerPathway Medtech, an ISO 13485:2016 certified and FDA registered company, provides contract manufacturing and packaging for e-merge portfolio companies. The facility is located in Santee, Eastern San Diego County, close to Evolve Medtech.
• Coastline InternationalsupportingStrategic or Co-development PartnerCoastline International has been a trusted contract manufacturing partner in Tijuana, Mexico, since 1982. Headquartered in San Diego, Coastline is a privately owned U.S. corporation operating under U.S. law. The company has supported leading companies across the medical device industry with reliable, cost-effective solutions and provides high volume, low cost manufacturing for e-merge portfolio companies.
• MMC International ServicessupportingStrategic or Co-development PartnerMMC International Services has been instrumental in designing and executing early-stage clinical trials, collaborating with key investigators across the US, Europe, South America, Australia, New Zealand and Asia. For emerging growth companies, MMC provides critical expertise in early clinical development strategy, study design, regulatory approval and study execution. MMC supports first-in-human (FIH) studies as well as broader clinical study and strategy needs for e-merge portfolio companies.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Lightstone Ventures: Lightstone Ventures is a sector-focused venture capital firm specializing in medical devices and biotechnology at the intersection of tech and life sciences. Its early-stage medtech thesis, partnership-driven model, and focus on therapeutic device categories closely mirror E-merge Capital's vertical strategy.
• Onset Ventures (now Aphelion Capital): Aphelion Capital (formerly Onset Ventures) is an early-stage venture capital firm focused primarily on medical devices, with a long history of company-building and strategic acquirer exits. Its sector focus, founder-led approach, and operating support model directly resemble E-merge Capital's vertical medtech model.
• Sanderling Ventures: Sanderling Ventures is one of the oldest medical device-focused venture capital firms, investing in early-stage cardiovascular, interventional, and surgical device companies. Its multi-generational medtech-only thesis and build-to-acquire playbook are directly comparable to E-merge Capital.
• Ascension Ventures: Ascension Ventures is a healthcare-focused venture capital firm that invests in medical devices, digital health, and healthcare services. Its emphasis on strategic acquirer relationships and provider-side thesis overlaps meaningfully with E-merge Capital's strategic-driven medtech model.
• Baird Capital — Life Sciences: Baird Capital's Life Sciences franchise invests in medical devices, diagnostics, and healthcare services at the early and growth stages. Its medtech-focused mandate and growth-stage orientation directly overlap with E-merge Capital's investment focus.
• Santé Ventures: Santé Ventures is an early-stage venture capital firm focused on medical devices and healthcare technology. Its founder-led approach, build-to-buy expertise, and Texas/San Diego footprint overlap with E-merge Capital's expertise in medtech investing.
• BioStar Capital: BioStar Capital is an early-stage venture capital and private equity firm focused on medical devices and healthcare technologies. Its deep operational expertise and strategic-acquirer relationships make it a close analog to E-merge Capital's vertical strategy.
• The Foundry (Foundry Group / Light & Co, predecessor): The Foundry is an early-stage medical device incubator that creates, funds, and supports startup medtech companies alongside strategic partners. Its deep medtech vertical focus, operating-led model, and tie-in with strategic acquirers make it a close comparable to E-merge Capital's vertical medtech approach.

Broad incumbents

• New Enterprise Associates (NEA) — Healthcare/Medtech Practice: NEA is a large multi-stage venture capital firm with a deep, long-standing healthcare and medical device practice. It regularly co-invests in and competes for the same early-stage medtech deals targeted by E-merge Capital, though NEA operates across many sectors.

Emerging players

• MedFocus / BioVentures Investors: BioVentures Investors is a medical device-focused early-stage venture capital firm. While smaller and less publicly active than other listed peers, its tight medtech focus and seed-stage orientation create partial overlap with E-merge's investment approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/e-merge-capital-partners

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about E-merge Capital Partners